Objective: To investigate the pattern of comorbidities and comedications in PSP patients compared to age-matched controls.

Background: Although progressive supranuclear palsy (PSP) is usually diagnosed in elderly, little is known about comorbidities and comedications in these patients.

Method: Cross-sectional data of PSP and control patients without neurodegenerative diseases were collected from German multicenter cohorts (DescribePSP, ProPSP, DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug-drug interactions were identified using AiDKlinik®.

Results: In total, 335 PSP and 275 age- and sex-matched control patients were included in this analysis. Although the number of comorbidities did not differ between the groups (PSP, 3.6 ± 2.4; controls, 3.4 ± 2.4; P = 0.263), the prevalence of neurological, psychiatric and cardiovascular diseases at first level of ICD-10 was higher in PSP. Diabetes mellitus, polyneuropathies and cerebrovascular diseases were more frequent in PSP at second level of ICD-10. PSP patients received more drugs (PSP, 5.2 ± 3.0; controls, 2.8 ± 2.4; P < 0.001), resulting in a higher percentage of patients with polypharmacy (PSP, 54.0%; controls, 20.4%; P < 0.001). Accordingly, the prevalence of potential drug-drug interactions was higher in PSP patients, especially severe and moderate interactions.

Conclusion: PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-comorbidity-and-comedication-profiles-of-patients-with-progressive-supranuclear-palsy-in-two-german-multicenter-cohorts-a-systematic-cross-sectional-analysis/